Xilio Therapeutics (XLO) Depreciation & Amortization (CF) (2020 - 2026)

Xilio Therapeutics has disclosed Depreciation & Amortization (CF) across 7 years of filings, most recently posting $344000.0 for Q1 2026.

• Depreciation & Amortization (CF) for Q1 2026 came in at $344000.0, down 30.78% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.4 million (down 18.26% YoY), and the FY2025 annual result was $1.5 million, down 6.27% from the prior year.
• Depreciation & Amortization (CF) came in at $344000.0 for Q1 2026 at Xilio Therapeutics, up from $323000.0 in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $499000.0 in Q1 2023 to a low of $323000.0 in Q4 2025.
• The 5-year median for Depreciation & Amortization (CF) is $445000.0 (2022), against an average of $428000.0.
• Across the five-year window, Depreciation & Amortization (CF) rose 25.71% in 2022 and slumped 30.78% in 2026, its largest moves.
• Xilio Therapeutics' Depreciation & Amortization (CF) stood at $489000.0 in 2022, then fell by 8.18% to $449000.0 in 2023, then decreased by 16.26% to $376000.0 in 2024, then fell by 14.1% to $323000.0 in 2025, then climbed by 6.5% to $344000.0 in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $344000.0 (Q1 2026), $323000.0 (Q4 2025), and $340000.0 (Q3 2025), per Business Quant data.